Literature DB >> 17600645

Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.

M A Kassem1, A A Abdel Rahman, M M Ghorab, M B Ahmed, R M Khalil.   

Abstract

Poorly-water-soluble compounds are difficult to develop as drug products using conventional formulation techniques. The use of nanotechnology to formulate poorly-water-soluble drugs as nanosuspensions offers the opportunity to address many of the deficiencies associated with this class of molecules. In the present study, the high pressure homogenization method used to prepare nanosuspensions of three practically insoluble glucocorticoid drugs; hydrocortisone, prednisolone and dexamethasone. The effect of particle size in the micron and nano-size ranges as well as the effect of viscosity of the nanosuspension on the ocular bioavailability was studied by measuring the intraocular pressure of normotensive Albino rabbits using shiØetz tonometer. The results show that compared to solution and micro-crystalline suspensions it is a common feature of the three drugs that the nanosuspensions always enhance the rate and extent of ophthalmic drug absorption as well as the intensity of drug action. In the majority of cases nanosuspensions extend the duration of drug effect to a significant extent. The data presented confirms that nanosuspensions differ from micro-crystalline suspensions and solution as ophthalmic drug delivery systems and that the differences are statistically, highly to very highly significant. The results confirm also the importance of viscosity of nanosuspension especially in increasing the duration of drug action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600645     DOI: 10.1016/j.ijpharm.2007.03.011

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  34 in total

Review 1.  Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2011-11-05       Impact factor: 4.575

Review 2.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

3.  Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation.

Authors:  Peng Quan; Dengning Xia; Hongze Piao; Hongyu Piao; Kai Shi; Yinnong Jia; Fude Cui
Journal:  AAPS PharmSciTech       Date:  2011-09-03       Impact factor: 3.246

Review 4.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

5.  Impacts of nanomedicines in ocular pharmacotherapy.

Authors:  Ailar Nakhlband; Jaleh Barar
Journal:  Bioimpacts       Date:  2011-06-09

6.  Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.

Authors:  Carolyn K Pan; Chandrasekar Durairaj; Uday B Kompella; Ogechi Agwu; Scott C N Oliver; Hugo Quiroz-Mercado; Naresh Mandava; Jeffrey L Olson
Journal:  J Ocul Pharmacol Ther       Date:  2011-05-16       Impact factor: 2.671

Review 7.  Nanocrystal for ocular drug delivery: hope or hype.

Authors:  Om Prakash Sharma; Viral Patel; Tejal Mehta
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

8.  Celecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluation.

Authors:  Anju Malkani; Abhijit A Date; Darshana Hegde
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

9.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

10.  Nanocrystals for the parenteral delivery of poorly water-soluble drugs.

Authors:  Bo Sun; Yoon Yeo
Journal:  Curr Opin Solid State Mater Sci       Date:  2012-12-01       Impact factor: 11.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.